FDA Approved: LOTEPREDNOL ETABONATE — Supplemental Application (Bausch & Lomb Americas Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Loteprednol Etabonate (Lotemax) from Bausch & Lomb Americas Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Conjunctivitis
• Keratitis
• Ocular Inflammation
• Postoperative Inflammation of the Eye
• Seasonal Allergic Conjunctivitis

Drugs mentioned

• Lotemax (Loteprednol etabonate)

Snippet

SUPPL AP for LOTEPREDNOL ETABONATE (LOTEPREDNOL ETABONATE)